Gross margin outlook
Search documents
Krystal Biotech targets global VYJUVEK expansion with Italy launch in H2 2026 while maintaining 90%–95% gross margin outlook (NASDAQ:KRYS)
Seeking Alpha· 2026-02-17 20:55
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...
